To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Objectives:
To compare the efficacy of monotherapy with anti-Vascular Endothelial Growth Factor
(ranibizumab or bevacizumab) with combined therapy with anti-Vascular Endothelial Growth
Factor and end-point-management grid laser photocoagulation for diabetic macular edema.
Study design:
Open-label non-randomized interventional study.
Study overview:
This study aims to look at the efficacy of treating diabetic macular edema (DME) with either
anti-Vascular Endothelial Growth Factor(anti-VEGF) monotherapy, compared with combination
therapy with anti-VEGF and End-Point-Management (EPM) grid laser photocoagulation, over a
period of 6 months.
Various sites from across Asia (Japan, South Korea, Hong Kong) will participate. Depending on
the availability of EPM laser, sites can either contribute to the 'Anti-VEGF monotherapy'
arm, or to the 'Combination therapy' arm.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Hong Kong
Collaborators:
Asahikawa Medical College Chungnam National University Hospital Eguchi Eye Clinic Hokkaido University Inje University Korea University Kyorin University Kyoto University Kyunghee University Kyungpook National University Kyungpook National University Hospital Kyushu University Nagasaki University Nagoya City University National University Hospital, Singapore Osaka Medical College Pusan National University Sun Cheon Hyang University Tokyo Medical University Hachioji Medical Centre University of Fukui Yamagata University Yeungnam University Yeungnam University Hospital